Future targets in endometriosis treatment: Targeting the endometriotic implant

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 324-328

  Nothnick, Warren B ^a,b   Zhang, Xuan ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Aromatase inhibitors; Endometriosis; Treatment

Indexed keywords

2 METHOXYESTRADIOL; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTIGESTAGEN; AROMATASE INHIBITOR; BUSERELIN; CALCITRIOL; CITRATE CALCIUM; DANAZOL; DESOGESTREL; ENDOSTATIN; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FADROZOLE; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; NAFARELIN; NORETHISTERONE ACETATE; PROGESTERONE; ROFECOXIB; STEROID; VASCULAR TARGETING AGENT; VASCULOTROPIN ANTIBODY; VITAMIN D; NITRILE; TRIAZOLE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; BONE DENSITY; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG INDUCED HEADACHE; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM TUMOR; ESTROGEN BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; HOT FLUSH; HUMAN; IMPLANT; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOLYSIS; OVARY CYST; PELVIS PAIN SYNDROME; REMISSION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VASOMOTOR DISORDER; ANIMAL; CHEMICAL STRUCTURE; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; AROMATASE INHIBITORS; CLINICAL TRIALS AS TOPIC; ENDOMETRIOSIS; FEMALE; HUMANS; MOLECULAR STRUCTURE; NITRILES; TRIAZOLES;

EID: 65349097334     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030324     Document Type: Review

References (44)

1. Gao, X.; Outley, J.; Botteman, M.; Spalding J.; Simon, J.A.; Pashos, C.L. Economic burden of endometriosis. Fertil. Steril., 2008, 86, 1561-72.
2. Liu, D.T.Y.; Hitchcock, A. Endometriosis: Its association with retrograde menstruation, dysmenorrhea, and tubal pathology. Br. J. Obstet. Gynaecol., 1986, 93, 859-86.
3. Nothnick W.B. Novel targets for the treatment of endometriosis. Expert Opin. Ther. Targets, 2004, 8, 459-71.
4. Valle, R.F.; Sciarra, J.J. Endometriosis: Treatment strategies. Ann. NY Acad. Sci., 2003, 997, 229-39.
5. Olive, D.L.; Pritss, E.A. The treatment of endometriosis. A review of the evidence. Ann. NY Acad. Sci., 2002, 955, 360-72.
6. Vercellini, P.; Cortesi, I.; Crosignani, P.G. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil. Steril., 1997, 68, 393-401.
7. Felberbaum, R.E.; Diedrich, K. Gonadotropin hormone-releasing antagonists: will they replace the agonists? Reprod. Biomed. Online, 2003, 6, 43-53.
8. Adashi, E.Y. Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod. Updat, 1994, 7, 1380-97.
9. Kiesel, L.; Schweppe, K.W.; Sillem, M.; Siebzehnrubl, E. Should add-back therapy for endometriosis be deferred for optimal results? Br. J. Obstet. Gynaecol., 1996, 103(Suppl 14), 15-7.
10. Surrey, E.S. Add-back therapy and GnRH agonist in the treatment of patients with endometriosis: can a consensus be reached? Addback consensus Working Group. Fertil. Steril., 1999, 71, 420-4.
11. Watanabe, Y.; Nakamura, G.; Matsuguchi, H.; Nozaki, M.; Sano, M.; Nakano, H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil. Steril., 1992, 58, 66-71.
12. Wheeler, J.M.; Knittle, J.D.; Miller, J.D. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am. J. Obstet. Gynecol., 1993, 169, 26-33.
13. Warnock, J.K.; Bundren, J.C.; Morris, D.W. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety, 1998, 7, 171-7.
14. Rachman, M.; Garfield, D.A.; Rachman, I.; Rachman, I.; Cohen, R. Lupron-induced mania. Biol. Psychiatry., 1999, 45, 243-4.
15. Noble, L.S.; Simpson, E.R.; Johns, A.; Bulun, S.E. Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab., 1996, 81, 174-9.
16. Bulun, S.E.; Yang, S.; Fang, Z.; Gurates, B.; Tamura, M.; Sebastian, S. Estrogen production and metabolism in endometriosis. Ann. N Y Acad. Sci., 2002, 955, 75-85.
17. Velasco, I.; Rueda, J.; Acién, P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol. Hum. Reprod., 2006, 12, 377-81.
18. Heilier, J.F.; Donnez, O.; Van Kerckhove, V.; Lison, D.; Donnez, J. Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum. Fertil. Steril., 2006, 85, 1516-8.
19. Attar, E.; Bulun, S.E. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil. Steril., 2006, 85, 1307-18.
20. Takayama, K.; Zeitoun, K.; Gunby, R.T.; Sasano, H.; Carr, B.R.; Bulun, S.E. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil. Steril., 1998, 69, 709-13.
21. Shippen, E.R.; West, W.J. Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil. Steril., 2004, 81, 1395-8.
22. Soysal, S.; Soysal, M.E.; Ozer, S.; Gul, N.; Gezgin, T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum. Reprod., 2004, 19, 160-7.
23. Amsterdam, L.L.; Gentry, W.; Jobanputra, S.; Wolf, M.; Rubin, S.D.; Bulun, S.E. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil. Steril., 2005, 84, 300-4.
24. Hefler, L.A.; Grimm, C.; van Trotsenburg, M.; Nagele, F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil. Steril., 2005, 84, 1033-6.
25. Ailawadi, R.K.; Jobanputra, S.; Kataria, M.; Gurates, B.; Bulun, S.E. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil. Steril., 2004, 81, 290-6.
26. Razzi, S.; Fava, A.; Sartini, A.; De Simone, S.; Cobellis, L.; Petraglia, F. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. Br. J. Obstet. Gynecol., 2004, 111, 182-4.
27. Fatemi, H.M.; Al-Turki, H.A.; Papanikolaou, E.G.; Kosmas, L.; De Sutter, P.; Devroey, P. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod. Biomed. Online, 2005, 11, 455-7.
28. Mousa, N.A.; Bedaiwy, M.A.; Casper, R.F. Aromatase inhibitors in the treatment of severe endometriosis. Obstet. Gynecol., 2007, 109, 1421-23.
29. Remorgida, V.; Abbamonte, H.L.; Ragni, N.; Fulcheri, E.; Ferrero, S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil. Steril., 2007, 88, 724-26.
30. Remorgida, V.; Abbamonte, L.H.; Ragni, N.; Fulcheri, E.; Ferrero, S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust. N. Z. J. Obstet. Gynaecol., 2007, 47, 222-5.
31. Yano, S.; Ikegami, Y.; Nakao, K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittel Forschung., 1996, 46, 192-5.
32. Kudoh, M.; Susaki, Y.; Ideyama, Y.; Nanya, T.; Mori, M.; Shikama, H. Inhibitory effects of a novel aromatase inhibitor, YM511, in rats with experimental endometriosis. J. Steroid Biochem. Mol. Biol., 1997, 63, 1-3.
33. Gazvani, R.; Templeton, A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction, 2002, 123, 217-26.
34. Barcz, E.; Rozewska, E.S.; Kaminski, P.; Demkow, U.; Bobrowska, K.; Marianowski-L. Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int. J. Gynaecol. Obstet., 2002, 79, 229-35.
35. Mahnke, J.L.; Dawood, M.Y.; Huang, J.C. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil. Steril., 2001, 73, 166-70.
36. Mclaren, J.; Prentice, A.; Charnock-Jones, D.S.; Smith, S.K. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum. Reprod., 1996, 11, 220-23.
37. Van Langendonckt, A.; Donnez, J.; Defrere, S.; Dunselman, G.A.J.; Groothuis, P.G. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises. Mol. Hum. Reprod., 2008, 14, 259-68.
38. McLaren, J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum. Reprod. Update, 2000, 6, 45-55.
39. Nisolle, M.; Casanas-Roux, F.; Anaf, V.; Mine, J.M.; Donnez, J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil. Steril., 1993, 59, 681-84.
40. Hull, M.L.; Charnock-Jones, D.S.; Chan, C.L.; Bruner-Tran, K.L.; Osteen, K.G.; Tom, B.D.; Fan, T.P.; Smith, S.K. Antiangiogenic agents are effective inhibitors of endometriosis. J. Clin. Endocrinol. Metab., 2003, 88, 2889-99.
41. Nap, A.W.; Griffioen, A.W.; Dunselman, G.A.J.; Bouma-Ter Steege, J.C.; Thijssen, V.L.; Evers, J.L.; Groothius, P.G. Antiangiogenesis therapy for endometriosis. J. Clin. Endocrinol. Metab., 2004, 89, 1089-95.
42. Becker, C.M.; Sampson, D.A.; Rupnick, M.A.; Rohan, R.M.; Efstathiou, J.A.; Short, S.M.; Taylor, G.A.; Folkman, J.; D'Amato, R.J. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil. Steril., 2005, 84 (Suppl 2), 1144-55.
43. Becker, C.M.; Sampson, D.A.; Short, S.M.; Javaherian, K.; Folkman, J.; D'Amato RJ. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil. Steril., 2006, 85, 71-7.
44. Becker, C.M.; Rohwer, N.; Funakoshi, T.; Cramer, T.; Bernhardt, W.; Birsner, A.; Folkman, J.; D'Amato, R.J. 2-Methoxyestradiol inhibits hypoxia-inducible factor-1?? and suppresses growth of lesions in a mouse model of endometriosis. Am. J. Pathol., 2008, 172, 534-44.